Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.42 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22951449 | 1.00 | LMNA (0.47) | LMNAMAPK1HTTL3MBTL1CYP1A2 | |
| SCHEMBL5686247 | 1.00 | LMNA (0.47) | LMNAMAPK1HTTL3MBTL1CYP1A2 | |
| SCHEMBL22212866 | 0.79 | ALDH1A1 (0.41) | LMNAMAPK1HTTL3MBTL1CYP1A2 | |
| SCHEMBL25751736 | 0.79 | ALDH1A1 (0.41) | LMNAMAPK1HTTL3MBTL1CYP1A2 | |
| SCHEMBL25641007 | 0.79 | LMNA (0.46) | LMNAMAPK1HTTL3MBTL1CYP1A2 | |
| SCHEMBL30762076 | 0.78 | ALDH1A1 (0.41) | LMNAHTTCYP1A2CYP2D6HSD17B10 | |
| SCHEMBL10298145 | 0.78 | ALDH1A1 (0.41) | LMNAHTTCYP1A2CYP2D6HSD17B10 | |
| SCHEMBL24769893 | 0.77 | SMN1; SMN2 (0.50) | LMNAL3MBTL1CYP1A2POLBMAPT | |
| SCHEMBL17298685 | 0.77 | CYP19A1 (0.45) | LMNAL3MBTL1POLBMAPTSMN1; SMN2 | |
| SCHEMBL25751738 | 0.76 | PKM (0.54) | LMNACYP1A2CYP2D6MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747366-A1 | PROCESS FOR THE REDUCTION OF AROMATIC IMINES WITH NOVEL IMINE REDUCTASES (IREDS) | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025017089-A1 | PROCESS FOR THE REDUCTION OF AROMATIC IMINES WITH NOVEL IMINE REDUCTASES (IREDS) | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-23 | — | — | WO | disclosed |
| US-20220400678-A1 | OXIME ETHER COMPOUND AND APPLICATION THEREOF | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| EP-1431316-B1 | The in situ polymerization of monoethylenically unsaturated monomers with oligomeric or polymeric secondary amines | BAYER MATERIALSCIENCE AG (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20040122169-A1 | Situ polymerization of monoethylenically unsaturated monomers with oligomeric or polymeric secondary amines | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
| EP-1431316-A1 | The in situ polymerization of monoethylenically unsaturated monomers with oligomeric or polymeric secondary amines | Bayer MaterialScience AG (DE) | 2004-06-23 | — | — | EP | disclosed |
| EP-1428837-A1 | The in situ polymerization of monoethylenically unsaturated monomers with oligomeric or polymeric secondary amines | Bayer MaterialScience AG (DE) | 2004-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220400678-A1 | OXIME ETHER COMPOUND AND APPLICATION THEREOF | CYP2E1, GALE, OGFOD1 | LMNA 4457/4885MAPK1 920/4885HTT 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.